Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
44.2M
-
Shares change
-
+892K
-
Total reported value, excl. options
-
$1.14B
-
Value change
-
+$27.8M
-
Put/Call ratio
-
1.59
-
Number of buys
-
63
-
Number of sells
-
-63
-
Price
-
$25.90
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q1 2021
151 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q1 2021.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44.2M shares
of 62.2M outstanding shares and own 71.09% of the company stock.
Largest 10 shareholders include FMR LLC (6.57M shares), BVF INC/IL (3.96M shares), RTW INVESTMENTS, LP (3.51M shares), BlackRock Inc. (3M shares), Consonance Capital Management LP (2.71M shares), Johnson & Johnson Innovation - JJDC, Inc. (2.45M shares), Farallon Capital Management, L.L.C. (2.43M shares), VANGUARD GROUP INC (2.14M shares), STATE STREET CORP (1.71M shares), and BAKER BROS. ADVISORS LP (1.44M shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.